Related Experiment Video
Updated: Aug 20, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
15-deoxy-delta12,14-prostaglandin-J2 inhibits expression of eNOS in human endothelial cells
Alicja Józkowicz1, Anneliese Nigisch, Birgitta Winter
1Faculty of Biotechnology, Jagiellonian University, Gronostajowa 7, Krakow 30-387, Poland. alicia@mol.uj.edu.pl
Abstract:
15-Deoxy-delta12,14-Prostaglandin-J2 (15d-PGJ2), an endogenous ligand of PPARgamma transcription factor, modifies expression of many genes involved in inflammation and angiogenesis. Enzyme which contributes to regulation of both these processes is endothelial nitric oxide synthase (eNOS). Our aim was to investigated the effect of 15d-PGJ2 on eNOS in human umbilical vein endothelial cells (HUVEC). We demonstrated that 24 h incubation of HUVEC with 15d-PGJ2 (1-10 microM) does not influence eNOS. On the contrary, the longer exposure (48-72 h) resulted in concentration-dependent inhibition of eNOS mRNA and protein expressions and led to reduction in eNOS enzymatic activity by approximately 50%. This effect was mediated by regulation of the transcription rate from eNOS promoter, what may be associated with inhibition of AP-1 binding capacity. The stability of mRNA was unchanged. Since none of the observed effects could be mimicked by troglitazone, a more potent PPARgamma ligand, we suppose that 15d-PGJ2 diminishes expression of eNOS via PPARgamma-independent mechanisms.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Regulation of Angiogenesis and Blood Supply
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Nitric Oxide Signaling Pathway

